Dr. Rai on the Treatment Paradigm for CLL
Kanti R. Rai, MD, professor, The Karches Center for Oncology Research, The Feinstein Institute for Medical Research, director, Center for Oncology and Cell Biology, Long Island Jewish Medical Center, professor, Medicine and Molecular Medicine, Hofstra Northwell School of Medicine, discusses the change in the treatment paradigm for chronic lymphocytic leukemia (CLL).
Kanti R. Rai, MD, professor, The Karches Center for Oncology Research, The Feinstein Institute for Medical Research, director, Center for Oncology and Cell Biology, Long Island Jewish Medical Center, professor, Medicine and Molecular Medicine, Hofstra Northwell School of Medicine, discusses the change in the treatment paradigm for chronic lymphocytic leukemia (CLL).
According to Rai, the treatment paradigm is changing, contrary to the enthusiasm and excitement when new drugs were approved years ago. These treatments are effective but are not cures.
There is a learning curve as to how to best use these new drugs and whether they can be combined to have an additive and synergistic benefit for the patient, explains Rai.
